A Study of Empirical Antifungal Therapy With Itraconazole
|ClinicalTrials.gov Identifier: NCT01706562|
Recruitment Status : Completed
First Posted : October 15, 2012
Last Update Posted : February 20, 2013
|Condition or disease||Intervention/treatment||Phase|
|Neutropenia||Drug: Itraconazole||Phase 4|
|Study Type :||Observational|
|Actual Enrollment :||138 participants|
|Official Title:||Retrospective Observation of Empirical Antifungal Therapy With Itraconazole|
|Study Start Date :||May 2011|
|Primary Completion Date :||September 2011|
|Study Completion Date :||September 2011|
Itraconazole intravenous (IV) 200 mg twice daily for 2 days, a total of 4 doses and then 200 mg once daily until clinically significant resolution of neutropenia.
- Success rate of itraconazole treatment when used for more than 7 days [ Time Frame: From 7 days to approximately 2 weeks ]Treatment success is achieved when neutropenia is resolved, ie, when the blood cells count is within the normal reference range.
- Success rate of itraconazole treatment until neutropenia is resolved [ Time Frame: Approximately 2 weeks ]Treatment success is achieved when neutropenia is resolved, ie, when the blood cells count is within the normal reference range.
- Drop out rate due to the lack of efficacy of itraconazole treatment [ Time Frame: Approximately 2 weeks ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01706562
|Study Director:||Janssen Korea, Ltd., Korea Clinical Trial||Janssen Korea, Ltd., Korea|